Co-Diagnostics, Inc. (CODX) stock

CODXNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30

$0.28−0.01 (-3.78%)

Close on Nov 11, 2026Market cap $1.74MP/E –Yield –

Co-Diagnostics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Co-Diagnostics's price to sales ratio was 1.9× on Nov 11, 2026, against 35.1× a year earlier. Over the last 5 years it ranged from 1.2× to 42.8×, with a median of 4.2×.

Price to Sales Ratio at the end of each year

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	1.9×	−14.1
2025	Dec 31, 2025	16.0×	+12.7
2024	Dec 31, 2024	3.3×	−5.5
2023	Dec 29, 2023	8.8×	+7.3
2022	Dec 30, 2022	1.5×	−1.0
2021	Dec 31, 2021	2.5×	−3.0
2020	Dec 31, 2020	5.5×	−127.6
2019	Dec 31, 2019	133.1×	–

Where these numbers come from

Parsed from the XBRL in Co-Diagnostics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-30 reverse split on Jan 2, 2026
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing